Kelso Pharma secures £140 million of acquisition funding

UK-based specialty pharma Kelso Pharma, which is backed by private equity investor Apposite Capital, announced that it has secured over £140 million ($180 million) of acquisition funding.

A proportion of the funding was used by Kelso Pharma in its acquisition of Alturix last month, the financial terms of which were not disclosed. The remaining facilities will be used to facilitate further acquisitions as the business continues to grow in the UK and across Europe.

The company noted that the milestone acquisition of Alturix in February represented a significant step forward in Kelso Pharma’s growth journey with the UK business doubling in size after the completion of the deal.